Single-nucleotide variants in microRNAs associated with breast cancer in women from western Mexico

Table 1 Characteristics of the patients from this study, n (%)

Characteristic	BrC patients
n = 71
Age at diagnosis, mean ± SD	54.06 ± 10.75
Patients with relatives with cancer
First-degree relative	22 (31.0)
Second-degree relative	10 (14.1)
With no relatives	39 (54.9)
Subtype of BrC
Lobular	13 (18.3)
Ductal	37 (52.1)
Mixed	5 (7.0)
Not determined	16 (22.5)
BrC hormone receptor status
HR+	38 (53.5)
HER+	9 (12.7)
Triple-negative BrC	5 (7.0)
Triple-positive BrC	13 (18.3)
Not determined	6 (8.5)
Molecular subtype
Luminal A	36 (50.7)
Luminal B	13 (18.3)
HER2	9 (12.7)
Triple negative	5 (7.0)
Not determined	8 (11.3)

BrC: Breast cancer; HR+: Hormone receptor positive; HER+: Human epidermal growth factor positive; HER2: Human epidermal growth factor receptor 2; Triple-positive BrC: Hormone receptor positive, human epidermal growth factor positive and progesterone receptor positive; Triple Negative BrC: Hormone receptor negative, human epidermal growth factor negative and progesterone receptor negative.